From personalizing clinical practice to aiding biomedical research, individualized clinical trials have been heralded as a solution to several problems plaguing modern medicine. But they’ve yet to be widely adopted.
The field is young, but predicting antigens produced by patients’ malignant cells could yield successful treatments for individuals with a range of cancer types.
A six-year study across the Tanzanian mountain’s slopes hints at how land-use practices will interact with a changing climate to influence ecosystems around the world.
The three-dimensional cell cultures are still in the development phase, but researchers are excited about their use to predict patients’ responses to various treatment options.
Researchers use 3-D printing technology to construct a brain cancer model that accurately recapitulated in vivo biology and predicted patient drug responses.
The expression of a slew of genes in psychiatric patients closely tracks pain intensity and predicts future emergency room visits, according to a study.
Comparing the cells of cancer patients who did and did not respond to the immunotherapy could reveal biomarkers to predict who should receive it in the first place.
By unraveling the molecular underpinnings of inherited blood disorders, the Boston Children’s Hospital researcher has provided the basis for therapies now being tested for beta-thalassemia and sickle cell disease.
Robert Guthrie’s blood test for the metabolic disorder phenylketonuria launched a worldwide movement to screen every baby for the disease soon after birth.
By testing multiple treatments in a single patient, hyperindividualized trial designs could offer more information about treatment efficacy in each participant, and about heterogeneity within and between patients.
There are currently more than two dozen ongoing Phase 1 and Phase 2 trials using different vaccine platforms such as DNA, RNA, synthetic long peptides, and dendritic cells.
